Functional and quality-of-life outcomes in patients with urinary incontinence implanted with a recharge-free sacral neuromodulation device

Blok B1, McCrery R2, Castellucci S3, Gauta J4, Lovejoy D5, Belal M6, Hashim H7, Boyles S8, Ehlert M9, Haas E10, Chapple K11, Harris-Hicks J12, Shah S13, Iorio M14, Xu X14, Waldeck H14, Pakzad M15

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 522
Open Discussion ePosters
Scientific Open Discussion Session 104
Thursday 8th October 2026
10:55 - 11:00 (ePoster Station 3)
Exhibition Hall
Neuromodulation Overactive Bladder Quality of Life (QoL) Incontinence Prospective Study
1. Erasmus Medical Center, Rotterdam, Netherlands, 2. UroHealth Partners, Omaha, NE, USA, 3. Florida Gulf Clinical Research, Bradenton, FL, USA, 4. Florida Bladder Institute, Naples, FL, USA, 5. Atrium Health, Macon, GA, USA, 6. Queen Elizabeth Hospital, Birmingham, UK, 7. Bristol Urological Institute, Bristol, UK, 8. The Oregon Clinic, Portland, OR, USA, 9. Minnesota Urology, Woodbury, MN, USA, 10. Houston Colon, Houston, TX, USA, 11. Northern General Hospital, Sheffield, UK, 12. Southern Shores Urogynecology, Myrtle Beach, SC, USA, 13. East Coast Institute of Research, Jacksonville, FL, USA, 14. Boston Scientific, Marlborough, MA, USA, 15. University College London Hospitals, London, UK
Presenter
Links

Poster

Abstract

Hypothesis / aims of study
Sacral neuromodulation (SNM) is a guideline-recommended treatment for overactive bladder (OAB), non-obstructive urinary retention, and faecal incontinence (FI).(1-3) The Axonics F15 trial objective is to assess safety and efficacy of a new recharge-free SNM device for OAB and FI treatment. Primary endpoint results in OAB patients are reported here.
Study design, materials and methods
This single-arm, multicentre, prospective clinical trial conducted in Europe (pivotal) and the USA (post-market) includes patients with primary OAB. The SNM system comprises an implantable neurostimulator, tined lead, and non-implantable components for device operation. Intraoperative and post-implant data were collected to measure 10-point mean improvement (minimal important difference (MID)) in ICIQ-OAB HRQL score from baseline to three months, and adverse events (AEs). Patients are followed for 12 months, anticipated to end in 2026.
Results
Of 79 total OAB patients enrolled at 14 sites, 75 were successfully implanted, and 73 followed through 3 months post-implant to assess the primary endpoint.

Of the patients, 84% are female, mean age 64 years, mean BMI 31.7, and mean time from OAB diagnosis to SNM implant >10 years. Mean 3-month ICIQ-OAB score improvement was significantly greater than the MID in the HRQL score (p <0.001), and for all sub-domains(Fig 1a). All changes in median domain scores exceeded the MID, and at least 69% of patients achieved or exceeded the MID across all domains (Fig. 1b).

According to the study satisfaction questionnaire taken at 3-Month(n=73), satisfaction with SNM was 80% for urinary urge incontinence and 79% for urinary frequency. Over 72% of patients experienced ≥50% reduction in urinary symptoms. Eighty-two percent (82%) would undergo the procedure again and 92% would recommend the SNM system to a family member or friend. To date, no unanticipated adverse device effects or serious AEs relative to the device and/or procedure have been reported. Device-related only events were reported in 14 (17.7%) patients, procedure-related only events were reported in 9 (11.4%) patients and events related to both the device and procedure were reported in 3 (3.8%) patients. Two patients required three revisions for non-serious AEs (two for a sensation of the lead in the lower back, one for no symptomatic improvement).  Two deaths were reported, unrelated to study device or procedure.
Interpretation of results
This study provides robust data that the recharge-free SNM system has a proven short-term safety and effectiveness profile in chronic OAB patients. The majority of patients (69%) demonstrated meaningful clinical improvement across all domains.
Concluding message
The Axonics F15 SNM system showed significant improvements in urinary incontinence-related quality-of-life and a favourable safety profile in patients with OAB over a 3-month period.
Figure 1 Figure 1: ICIQ-OAB improvement from baseline to 3 months (n=73) Panel A: ICIQ-OAB scores at baseline and 3 months Statistics are mean ± Standard Error. All p-values for domain scores at baseline and 3 months using one-sided paired t-tests are significant
References
  1. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985.
  2. Ginsberg DA, Boone TB, Cameron AP, Gousse A, Kaufman MR, Keays E, Kennelly MJ, Lemack GE, Rovner ES, Souter LH, Yang CC, Kraus SR. The AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up. J Urol. 2021 Nov;206(5):1106-1113. doi: 10.1097/JU.0000000000002239.
  3. Bordeianou LG, Thorsen AJ, Keller DS, Hawkins AT, Messick C, Oliveira L, Feingold DL, Lightner AL, Paquette IM. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Fecal Incontinence. Dis Colon Rectum. 2023 May 1;66(5):647-661. doi: 10.1097/DCR.0000000000002776.
Disclosures
Funding Axonics, Inc. (now Boston Scientific Corporation) Clinical Trial Yes Registration Number NCT06186765 RCT No Subjects Human Ethics Committee WCG IRB, Columbia University Medical Center Institutional Review Board, West of Scotland Research Ethics Service Helsinki Yes Informed Consent Yes AI Not at all
20/11/2026 23:32:11